ID Genomics Awarded Prestigious Longitude Prize Discovery Award

By Kaveri Parker 3 years ago
Home  /  News  /  ID Genomics Awarded Prestigious Longitude Prize Discovery Award

Seattle-based ID Genomics, Inc. has received a grant from the Longitude Prize Discovery Awards, a seed funding initiative that supports teams competing for the prestigious Longitude Prize. Organized by innovation foundation Nesta with Innovate UK as funding partner, the Longitude Prize is a £10 million fund aimed at creating an affordable, rapid and easy-to-use diagnostic test for bacterial infections, so the right antibiotics can be given at the right time. Over 240 teams from 40 countries are vying for the Prize.

ID Genomics is advancing innovative “bacterial fingerprinting” technology that could help cut prescription errors and curb overuse of broad-spectrum antibiotics by making the antibiotic prescribing process faster and more accurate. At scale, this approach could improve patient outcomes and help slow the spread of antibiotic-resistant bacteria.

With antimicrobial resistance projected to cause 10 million deaths each year by 2050, the seed funding program seeks to spark much-needed innovation toward a game-changing point-of-care diagnostic. ID Genomics is among 13 organizations from Australia, Belgium, India, Israel, the Netherlands, the USA and the United Kingdom to receive the Award. The Discovery Awards are funded through a £250,000 grant from MSD, known as Merck in the United States and Canada, a global healthcare company.

“Receiving a Longitude Prize Discovery Award is a genuine honor,” said Evgeni Sokurenko, Founder of ID Genomics and Professor of Microbiology at the University of Washington School of Medicine.

“Our team, backed by partners in our clinical consortium, is working relentlessly to advance our core technology so we can track, contain and treat antibiotic-resistant superbugs worldwide. We look forward to continuing to compete for the Longitude Prize,” added Kaveri Parker, ID Genomics President and CEO.

ID Genomics’ CLoNeTTM rapid diagnostic test can identify the bacterial fingerprint of different strains of key pathogens (such as Escherichia coli) in urinary tract infections (UTIs) in under 30 minutes. That fingerprint is then compared against the company’s BactNetTM reference database, which holds thousands of bacterial strains collected worldwide along with their antibiotic response profiles. Armed with specific information about a given strain’s likely resistance, a patient can be prescribed the antibiotic best matched to their infection. This ‘big data’ approach combines epidemiological surveillance, antimicrobial stewardship and molecular diagnostics to deliver precision medicine right at the point-of-care.

Earlier this year, peer-reviewed findings from observational clinical research showed that ID Genomics’ “bacterial fingerprinting” technology could improve antibiotic prescribing and reduce prescription errors and overuse of broad-spectrum antibiotics, potentially improving patient outcomes and slowing the spread of antibiotic-resistant bacteria. The paper, “Bacterial Clonal Diagnostics as a Tool for Evidence-Based Empiric Antibiotic Selection,” appeared in the Open Access journal PLOS ONE. Beyond UTIs, ID Genomics intends to extend its technology to identify and treat a broad range of bacterial infections.

About ID Genomics
ID Genomics is a Seattle-based health technology company developing rapid point-of-care diagnostics for infectious disease diagnosis and treatment. Its proprietary CLoNeT™ and BactNet™ DNA fingerprinting-based diagnostics system draws on key discoveries in microbiology and bacterial genomics to improve patient outcomes, lower costs and ultimately reduce the spread of infectious diseases. Research has shown that ID Genomics’ technology gives health care providers information about essential characteristics of the infecting bacteria, enabling them to accurately prescribe the right antibiotics for infectious diseases in under 30 minutes. More information is available online at www.idgenomics.com.

Media Contacts
John Williams, Scoville PR for ID Genomics
206-625-0075 x1, [email protected]  
Kasia Murphy, Media Manager, Nesta 
t: +44 2074382610 m: +447929800765
[email protected]
Category:
  News
this post was shared 0 times
 000